Fig. 6.

Dicer deletion in astrocytes inhibits remyelination after lysolecithin-induced demyelination. A Schematic diagram of the time course of tamoxifen (TMF) treatment and histology; B Counter-immunostaining for GFAP (white arrowheads indicating astrocytes in B). Scale bars, 50 μm (middle and left panels) and 20 µm (right panels); C Schematic diagram showing the time course of tamoxifen (TMF) treatment, lysolecithin injection, and histology. Representative images and quantification of MBP expression in the lesion (dotted areas) reveal cumulative nuclei (DAPI). Scale bar, 200 µm. D, E Representative images and quantification of CC1- and GFAP-positive cells in the lesion (dotted areas). Scale bars, 50 µm (D), 100 µm (E). F mGFP in the SVZ and counter-immunostaining for NG2 (OPCs) and Olig2 (OLs) in the hGFAP-CreERT; mT/mG brain. Scale bar, 50 µm. Error bars represent the mean ± SEM. *P < 0.05, Student’s t-test, Dicer-cKO vs control, n = 3–4 for all experiments.